



Annual Meeting of Stockholders

April 17, 2017



Esperion's Commitment to Bempedoic Acid



Significant Market Opportunity

- Committed to applying our **scientific expertise** in cholesterol biology to transform the lives of the **millions of patients** still suffering with elevated LDL-cholesterol levels, especially those considered statin intolerant
- Addressing significant unmet needs
- Total potential addressable market **exceeding \$20B**



Pathway to Approval Clearly-Defined

- **Confirmed regulatory pathway to approval for an LDL-C lowering indication**
- Global pivotal Phase 3 program supports approval for an LDL-C lowering indication in the U.S. and Europe
- Attractive safety and tolerability profile and **consistent LDL-C lowering efficacy** in multiple clinical trials across multiple patient populations
- Lipid management team with **extensive experience** developing and commercializing innovative LDL-C lowering therapies



Well Funded with Lean, Efficient Operating Model


- ~\$243M in cash at year-end 2016
- Cash resources to fund operations through:
 - Anticipated **completion of the bempedoic acid Phase 3 clinical development program** by mid-2018; and
 - On track to submit **NDA/MAA to global regulatory authorities** for an LDL-C lowering indication by 1H 2019

Esperion

The Lipid Management Company

- We are dedicated to transformation of the LDL-C lowering landscape through our deep understanding of cholesterol biology, which is manifested in bempedoic acid
- Our team of lipid management experts is “data-driven” to generate preclinical, nonclinical and clinical results to confirm the value of bempedoic acid
- With two Phase 3 convenient, complementary, cost-effective, non-statin, oral, once-daily LDL-C lowering therapies we are committed to building long-term value for patients, physicians, payers and stockholders
- We will continue to work to ensure global approval and commercial success of bempedoic acid to benefit the millions of the high risk patients with hypercholesterolemia and/or statin intolerance in need of additional LDL-cholesterol lowering alternatives

The Evolution of Bempedoic Acid



Esperion's 2017 Corporate Milestones

Q1 2017

Initiated Open-Label Extension Study of Phase 3 Long-Term Safety Study

Initiated Phase 2 Triplet Oral Therapy Study (bempedoic acid+ezetimibe+atorvastatin)

Q2 2017

Announcement of Bempedoic Acid & Ezetimibe (BA+EZ) Clinical Development and Regulatory Plans

Presentation / Publication of 1002-035 Full Results

Initiate Phase 2 Study of Bempedoic Acid Added-On to PCSK9i

2H 2017

Expected Completion of Enrollment for All Global Pivotal Phase 3 LDL-C Lowering Efficacy Studies

Announcement of Phase 2 Triplet Oral Therapy Top-Line Results

Esperion
The Lipid Management Company

www.esperion.com

